Nantahala Capital Management’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Nantahala Capital Management’s Portfolio MACK Stock Details MACK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-111,148	Closed	-$1.37M	–	152
2023 Q2	$1.37M	Sell	111,148 -80,118	-42%	-$1M	0.13%	85
2023 Q1	$2.35M	Sell	191,266 -18,734	-9%	-$220K	0.18%	71
2022 Q4	$2.41M	Sell	210,000 -219,596	-51%	-$1.81M	0.16%	73
2022 Q3	$1.61M	Sell	429,596 -61,913	-13%	-$286K	0.1%	79
2022 Q2	$2.92M	Sell	491,509 -25,308	-5%	-$143K	0.15%	76
2022 Q1	$3.27M	Sell	516,817 -53,154	-9%	-$299K	0.14%	74
2021 Q4	$2.23M	Hold	569,971	–	–	0.08%	104
2021 Q3	$2.75M	Sell	569,971 -1,975	-0.3%	-$10.3K	0.09%	97
2021 Q2	$3.65M	Sell	571,946 -37,028	-6%	-$244K	0.1%	98
2021 Q1	$3.82M	Sell	608,974 -142,869	-19%	-$1.02M	0.11%	88
2020 Q4	$5.18M	Sell	751,843 -100	-0%	-$493	0.16%	89
2020 Q3	$3.01M	Buy	751,943 +4,308	+0.6%	+$15.8K	0.09%	93
2020 Q2	$2.49M	Hold	747,635	–	–	0.08%	99
2020 Q1	$1.61M	Hold	747,635	–	–	0.06%	95
2019 Q4	$2.35M	Hold	747,635	–	–	0.07%	80
2019 Q3	$3.36M	Sell	747,635 -75,509	-9%	-$377K	0.12%	78
2019 Q2	$3.92M	Buy	+823,144	New	+$3.9M	0.12%	78

Other funds holding MACK

WSL

Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Sepio Capital Salt Lake City, Utah $1.99B AUM 22.34% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

WIM

Wittenberg Investment Management Carlisle, Massachusetts $269M AUM 28.17% 1-Year Est. Return

Nantahala Capital Management's MACK Position: Q3 2023 in Review

Nantahala Capital Management sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q3 2023, closing a stake of 111,148 shares — an estimated $1.37M sold.

Nantahala Capital Management first reported a position in MACK in Q2 2019 and held it in 17 quarters. The position peaked at $5.18M in Q4 2020. 63 funds tracked by Wall St. Rank hold MACK as of Q3 2023.

Nantahala Capital Management reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
Nantahala Capital Management sold 111,148 Merrimack Pharmaceuticals, Inc. shares in Q3 2023, an estimated $1.37M.
Nantahala Capital Management first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2019 and held it in 17 quarters.
Nantahala Capital Management's Merrimack Pharmaceuticals, Inc. position peaked at $5.18M in Q4 2020.
63 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q3 2023.

Based on Nantahala Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.